We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
Boston Scientific (BSX - Free Report) closed the most recent trading day at $42.04, moving +1.11% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 0.47% for the day. At the same time, the Dow added 0.1%, and the tech-heavy Nasdaq lost 1.25%.
Shares of the medical device manufacturer witnessed a loss of 7.52% over the previous month, trailing the performance of the Medical sector with its loss of 3.97%, and the S&P 500's gain of 1.15%.
Analysts and investors alike will be keeping a close eye on the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to go public on October 28, 2026. The company is forecasted to report an EPS of $0.76, showcasing a 1.33% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $5.17 billion, showing a 2.12% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.25 per share and a revenue of $21.17 billion, signifying shifts of +6.21% and +5.45%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Boston Scientific. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.3% decrease. Boston Scientific is holding a Zacks Rank of #4 (Sell) right now.
In terms of valuation, Boston Scientific is currently trading at a Forward P/E ratio of 12.78. This expresses a discount compared to the average Forward P/E of 19.24 of its industry.
We can also see that BSX currently has a PEG ratio of 1. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BSX's industry had an average PEG ratio of 1.73 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 98, placing it within the top 40% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Boston Scientific (BSX) Advances While Market Declines: Some Information for Investors
Boston Scientific (BSX - Free Report) closed the most recent trading day at $42.04, moving +1.11% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 0.47% for the day. At the same time, the Dow added 0.1%, and the tech-heavy Nasdaq lost 1.25%.
Shares of the medical device manufacturer witnessed a loss of 7.52% over the previous month, trailing the performance of the Medical sector with its loss of 3.97%, and the S&P 500's gain of 1.15%.
Analysts and investors alike will be keeping a close eye on the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to go public on October 28, 2026. The company is forecasted to report an EPS of $0.76, showcasing a 1.33% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $5.17 billion, showing a 2.12% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.25 per share and a revenue of $21.17 billion, signifying shifts of +6.21% and +5.45%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Boston Scientific. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.3% decrease. Boston Scientific is holding a Zacks Rank of #4 (Sell) right now.
In terms of valuation, Boston Scientific is currently trading at a Forward P/E ratio of 12.78. This expresses a discount compared to the average Forward P/E of 19.24 of its industry.
We can also see that BSX currently has a PEG ratio of 1. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BSX's industry had an average PEG ratio of 1.73 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 98, placing it within the top 40% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.